Phase 2 N=16 Supporting the Health of Adults Undergoing Orthopedic Surgery During the Recovery Period
Delirium
Primary: Percentage of Participants With Delirium Using the CAM Over Time — 14; 44; 64; 64 percentage of participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=20 Trilogy Stereotactic Body Radiotherapy for Pancreatic Cancer
Pancreatic Cancer
Primary: Rate of Local Control — 15 participants
Phase 2 N=20 Breakthrough Dyspnea Fentanyl Study in Cancer Patients
Advanced Cancers · Dyspnea
Primary: Retention Rate — 100; 100 percentage of participants
Phase 2 N=102 Docetaxel With Rapid Hormonal Cycling as a Treatment for Patients With Prostate Cancer
Prostate Cancer
Primary: PSA of <_ 0.05 ng/ml After Radical Prostatectomy or Radiation Therapy and PSA <_ 2.0 ng/ml for Patients With Clinical Metastases Without Prior Definitive Therapy — 9…
Phase 2 N=47 A Study of Induction and Maintenance Treatment With MabThera (Rituximab) in Patients With Indolent B-Cell Nonfollicular Lymphomas
Non-Hodgkin's Lymphoma
Primary: Percentage of Participants Remaining Failure-Free After 2 Years From Treatment Start Date — 73.9 percentage of participants — p=<0.0001
Phase 2 N=11 Bevacizumab and Docetaxel in Treating Older Patients With Stage III or Stage IV Non-Small Cell Lung Cancer
Lung Cancer
Primary: Survival — 75 percentage of participants surviving
Phase 2 N=77 Alpha-1-Antitrypsin (AAT) To Treat Emphysema In AAT-Deficient Patients (EXACTLE)
Alpha 1-Antitrypsin Deficiency
Primary: The Progression Rate of Emphysema Determined by Change in 15th Percentile of Lung Density Measured by Annual CT Scan of the Whole Lung — 47.980; 45.477; 45.085; 41.354…
Phase 2 N=42 Bortezomib in Treating Patients With Stage IIIB or Stage IV Lung Cancer
Adenocarcinoma of the Lung · Bronchoalveolar Cell Lung Cancer · Non-small Cell Lung Cancer
Primary: Objective Response Rate With Bortezomib Evaluated by Both RECIST Criteria and Computer-assisted Image Analysis. — 5 percentage of responders
Phase 2 N=262 Dose-finding Study of Hexaminolevulinate (HAL) Photodynamic Therapy (PDT) to Treat Cervical Neoplasia
Cervical Intraepithelial Neoplasia
Primary: Comparison of Lesion Response Rates of Three Different Doses of HAL PDT and Placebo at 3 Months After Treatment. — 95; 69; 63; 57 percentage of patients
Phase 2 N=19 Effects of Pentazocine Versus Lorazepam on Manic Symptoms
Bipolar Disorder · Schizoaffective Disorder · Manic Disorder
Primary: Mania Acute Rating Scale (MACS) — 3.9; 6.4 units on a scale — p=0.22
Phase 2 N=360 Renal Optimization Strategies Evaluation in Acute Heart Failure and Reliable Evaluation of Dyspnea in the Heart Failure Network (ROSE) Study
Acute Heart Failure
Primary: Change in Cystatin C — .12; .11; .07 mg/L
Phase 2 N=72 Deposition of Inhaled Prolastin in Cystic Fibrosis Patients
Cystic Fibrosis
Primary: Change in Free Elastase in Induced Sputum From Baseline to Week 4 — -7.42; 6.11 ug/mL — p=0.197
Phase 2 N=12 Efficacy and Safety Study of Genetically Targeted Enzyme Replacement Therapy for Advanced Heart Failure
Heart Failure, Congestive · Dilated Cardiomyopathy
Primary: Phase 2: Incidence of Treatment-emergent Adverse Events (TEAE) at 12 Months — 100; 100; 88.9; 92.9 percentage of participants
Phase 2 N=79 A Study to Evaluate the Efficacy and Safety of CNTO328 Plus Best Supportive Care in Multicentric Castleman's Disease
Multicentric Castleman's Disease
Primary: Percentage of Participants Who Achieved Durable Tumor and Symptomatic Response - by Independent Radiology Review — 0; 34 Percentage of participants — p=0.0012
Phase 2 N=132 Safety/Efficacy Study of Subcutaneously Injected Prandial Insulins Compared to Insulin Lispro Alone in Patients With Type 2 Diabetes Mellitus
Diabetes Mellitus, Type II
Primary: Change From Baseline in Glycosylated Hemoglobin A1C (HbA1C) at the End of Each Treatment Period — -0.48; -0.46 percentage of HbA1C — p=0.3876